Rituximab-mediated interactions between CD20 and FcγRIIb on B-cell lymphoma increased the internalization of the rituximab/CD20 immune complex and prevented immune regulation of rituximab-opsonized B-cell lymphoma [6–9]. Here, FCGR2B is linked to B-cell non-Hodgkin lymphoma.